The infusion rate should be reduced by 50% in case of nonserious infusion reactions In patients who develop serious infusion reactions, cetuximab should be discontinued immediately and permanently ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Penile Cancer. According to GlobalData, Phase I drugs for Penile Cancer does ...

“Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin,” the authors concluded. “These findings are ...

Cetuximab is an epidermal growth factor (EGFR) inhibitor that is used to treat metastatic colorectal cancer. However, cetuximab produces an acne-like rash in over 80% of patients treated. Although ...